Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Nov 30, 2016
Insider Transaction Report
Form 4
Getman Daniel P
Director
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-28−16,201→ 63,799 totalExercise: $6.80From: 2015-05-09Exp: 2024-05-09→ Class A Common Stock (16,201 underlying) - Sale
Common Stock, Class A
2016-11-28$16.89/sh−16,201$273,635→ 0 total - Exercise/Conversion
Common Stock, Class A
2016-11-28$6.80/sh+16,201$110,167→ 16,201 total - Exercise/Conversion
Common Stock, Class A
2016-11-29$6.80/sh+3,799$25,833→ 3,799 total - Sale
Common Stock, Class A
2016-11-29$16.75/sh−3,799$63,633→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-29−3,799→ 60,000 totalExercise: $6.80From: 2015-05-09Exp: 2024-05-09→ Class A Common Stock (3,799 underlying)
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 to $16.95, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range.